Atorvastatin calcium (ATV) is a selective competitive inhibitor of HMG CoA reductase characterized by poor aqueous solubility leading to inadequate bioavailability. The present study was designed to develop solid dispersion of atorvastatin (SDA) to improve the solubility and dissolution properties of ATV and evaluation of its in-vivo efficiency in streptozotocin (STZ) induced diabetic mice. Formulations of SDA were prepared by solvent evaporation method using PEG-4000 alone and/or mixture of PEG-4000 and Carplex-80 as carrier in different ratios. Solid-state analyses of SDA were performed to characterize the physicochemical properties of newly developed SDA by differential scanning calorimetry (DSC), powder x-ray diffractometry (PXRD), fourier transformed infrared spectra (FTIR) and scanning electron microscopy (SEM). DSC and PXRD showed that the crystallinity of drugs was notably decreased during the preparation of SDA. FTIR and SEM also demonstrated the conversion of ATV from amorphous to crystalline state resulting in improved solubility. Among formulations, SDA-5 showed significant enhancement of in-vitro drug release (around 2 fold higher) as compared to pure ATV. Further, in-vivo study was conducted to evaluate the effects of a newly developed ATV loaded solid dispersion on glycemic control, lipid profile, liver enzyme and histopathology in STZ induced diabetic mice. Oral administration of SDA significantly lowered the blood glucose levels during the course of treatment. Treatment with SDA significantly improved lipid profiles better than ATV alone and the effect was dose-dependent. After one week of SDA treatment significantly decreased liver weights as result of lipid clearance and the hepatocytes regained their normal architecture, and these beneficial effects can be correlated with the reduction of SGPT levels. The results demonstrated that, SDA exerted better glycemic control, lipid lowering effect and organ protection (liver and pancreas) than that of conventional ATV in STZ induced diabetic mice. The mechanism by which SDA conferred better improvement in diabetic conditions can be partially explained by enhancement of solubility and dissolution rate when ATV is loaded in solid dispersion.
Introduction
Most of the newly discovered chemical entities, in spite of therapeutic activity, have low aqueous solubility and poor membrane permeability leading to poor absorption in the gastrointestinal tract (GIT) as well as bioavailability in systemic circulation [1] . A drug with poor aqueous solubility will typically exhibit dissolution rate limited absorption and/or permeation rate limited absorption even though it shows good aqueous solubility. Hence, two areas of pharmaceutical research that can focus on improving the oral bioavailability of active pharmaceutical ingredients include enhancing aqueous solubility leading to increased dissolution rate of poorly water-soluble drugs and enhancing permeability of poorly permeable drugs [2] .
Atorvastatin (ATV), a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis [3] [4] . It belongs to BCS class II drug having high permeability but low aqueous solubility and is associated with a poor bioavailability and a short half-life [5] . In order to get beneficial therapeutic effects, its water solubility needs to be increased. Thus, formulation of ATV should be such that it has enough aqueous solubility. ATV is the most preferred drug among statins used to treat moderate to severe familial or non-familial hypercholesterolemia [3] [4] . It is also indicated for different types of cardiovascular disease [6] [7] [8] . It was reported that ATV treatment lower blood sugar in diabetic mice accompanied by the benefits of insulin enhancement and body weight increment [9] .
Many approaches have been developed to improve solubility and thus, to enhance the dissolution rate and oral bioavailability of poorly soluble drugs [10] - [15] . Physical modifications often aimed to increase the surface area, solubility and wettability of the powder particles and are therefore, focused on particle size reduction and/or conversion to amorphous states. In many studies, it is reported that amorphous systems is efficient for the enhancement of dissolution and bioavailability. Solid dispersion (SD) is a unique and promising approach for improving the oral absorption and bioavailability of atorvastatin [16] - [22] .
The SD enhances the drug solubility by various mechanisms either by reducing the particle size or improving bioavailability or increasing porosity and converting the crystalline forms of drug into amorphous form. Although SD technique was used to improve the solubility and dissolution rate of ATV but recently a number of formulations have been developed for the enhancement of solubility and dissolution profile of the drug [13] [14] [23] [24] . Therefore, the aims of the study were to enhance the solubility and dissolution profile of the ATV by preparing atorvastatin calcium solid dispersion (SDA) and in-vivo evaluation of its efficacy in STZ induced diabetic mice.
Materials and Methods

Materials
STZ was purchased from Sisco Research Laboratories Pvt. Ltd. (India) and silica (Carplex-80) was purchased from Merck Company (Germany). Serum total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) and serum glutamate pyruvate transaminase (SGPT) was determined using commercial kit purchased from Human Company (Germany). Pure ATV, used as a research sample, was a generous donation by Square Pharmaceuticals Ltd. Pabna, Bangladesh. All other chemicals and solvents used were of analytical grade.
Preparation of SDA
The SDA was prepared using the solvent evaporation method at different ratio of drug and carrier (Table 1) . Briefly, accurately weighed ATV powder was dissolved in appropriate volume of ethanol into which variable amounts of PEG-4000 and/or combination of both PEG-4000 and Carplex-80 were added and dispersed in the drug solution under continuous stirring by magnetic stirrer with 200 rpm at 50˚C to allow proper loading of the drug into carrier and to evaporate the solvent from the dispersion system. After complete evaporation of 
In-Vitro Dissolution Study
The pharmaceutical performance of pure ATV in powder form and SDA was evaluated using in vitro dissolution tests. The tests were performed according to the USP 24 method 2 (paddle method) using a dissolution tester (Tianjin Guoming Medicinal Equipment Co., Ltd.). The media employed for testing dissolution was water. Sample equivalent to 25 mg ATV powder was spread onto the surface of the dissolution medium (500 ml), which was thermostatically maintained at 37.0˚C ± 0.5˚C with 50 rpm.
At the specified times (5, 15, 30, 45, 60, 90 , and 120 min), 10 ml samples were withdrawn from dissolution vessel and filtered, from which 1 ml of solution is transferred to a volumetric flask and diluted to 5 times for assaying ATV content by measuring absorbance at 245 nm using a UV-spectrophotometer. An equal volume of water was replaced immediately to keep the volume of dissolution medium constant. Three replicates of each dissolution test were carried out and calculated mean values of cumulative drug release were used while plotting the release profile. To determine the concentration of ATV a standard calibration curve was plotted using 5 standard concentrations (1 µg/ml, 3 µg/ml, 5 µg/ml, 10 µg/ml and 20 µg/ml). Also, three replicates of each dissolution test were carried out and mean values were calculated. The mean concentration of ATV was plotted against time to derive the dissolution profile. The standard solution was prepared by dissolving 25 mg ATV in 50 ml methanol and mixed properly.
From the solution appropriate quantity of aliquot was transferred to 50 ml volumetric flask and diluted with methanol to get the desired concentration of 1 µg/ml, 3 µg/ml, 5 µg/ml, 10 µg/ml and 20 µg/ml. 
Characterization of Prepared
Powder X-Ray Diffraction (PXRD)
An X-ray diffractometer (RAD-C, Rigaku Denki Co. Ltd., Tokyo, Japan) was used for the diffraction studies. The samples were exposed to Cu-Kα radiation (30 kV, 50 mA) and scanned from 3˚ -40˚, 2θ at a scanning rate of 5˚/min.
Samples used for PXRD analysis were pure ATV, PEG-4000, Carplex-80, PEG-4000 + Carplex-80 and the SDA. 
Scanning Electron Microscopy (SEM)
The shape, surface, and cross-sectional morphology of ATV, PEG-4000, Carplex-80, PEG-4000 + Carplex-80 and the SDA were observed using a scanning electron microscope (SSX-500, Shimadzu, and Tokyo, Japan) after platinum
metallization. An accelerating voltage of 15 kV was used. 
Experimental Animals
Protocol Design
To prepare the experimental diabetic animals, the mice were fasted for 12 hours, then freshly prepared STZ solution (dissolved in sodium citrate buffer; pH 4.2) was given into mice by intraperitoneal injection (60 mg/kg, body weight) for five consecutive days. After overnight fasting, blood glucose levels were measured by glucometer (One Touch Ultra, Japan) using a blood sample from tail-vein of mice. Blood glucose levels that were higher than 300 mg/dl considered as diabetic mice [25] . Among the six formulations, SDA-5 (ATV + PEG-4000 + Carplex-80, 1:2:3 ratios) was used for in-vivo studies on the basis of its greater dissolution rate as compared to other formulations and/or pure ATV.
After induction of diabetes, rats were divided into four groups for the oral administration of drugs and/or vehicle and the groups were as follows: 1) di- and each group comprised of five animals (n = 5).
Measurement of Body Weights, Organ Weights and Glucose Level
The body weight (BW) and fasting blood glucose level of mice from each group was measured on 0, 1, 3, 5, and 7 day. At the end of the experiments all mice were fasted overnight with free access of water. Animals were anesthetized using diethyl ether, chest opened and blood samples were withdrawn directly from abdominal aorta at retroperitoneal space and poured into blood collecting tube [26] . The blood samples were centrifuged at 4000 rpm for 10 minutes (Ultra-centrifuge, Centurion, UK) and the serum samples were stored at −40˚C until further biochemical estimation. After sacrificing liver and pancreas were removed and cleaned of the surrounding tissues. The organ weights (OW) were measured immediately and the ratio of organ weights to body weight ratio (gm/kg) were calculated. Then, the parts of liver and pancreas were stored in 10% formalin for histopathology.
Biochemical Estimations
The serum concentration of TC, TG and HDL were measured colorimetrically by photometric colorimeter (ERMA Inc., Japan) using commercially available wet reagent diagnostic kits (Human, Germany). Serum low density lipoprotein (LDL) was determined from TC, TG and HDL by using Friedewald formula [27] :
The concentration of SGPT was determined quantitatively by photometric method using commercial kit (Human, Germany).
Histopathological Study
The histopathological studies of liver and pancreas were carried out at the Department of Pathology, Rajshahi Medical College, Rajshahi, Bangladesh. Briefly, livers from each group were fixed in PBS containing 10% formalin. The tissues were washed in running tap water, dehydrated in the descending grades of isopropanol and finally cleared in xylene. The tissues were then embedded in molten paraffin wax. After embedding in paraffin, several transverse sections (5 μm) were cut from the mid organ level by microtome machine and stained with hematoxylin-eosin (HE). The specimens were observed under light microscope with digital camera for any structural changes and the microscopic photographs were processed using software provided by Optika Co., Italy.
Statistical Analysis
Data were expressed as mean ± standard error of mean (SEM 
Results
In-Vitro Dissolution Study
The drug release data obtained for ATV and formulations SDA-1 to SDA-6 are shown in Table 2 . After 120 min, the cumulative percent drug released was higher with SDA-1 to SDA-6 than that of pure ATV. From the in vitro drug release profile, it can be seen that formulation SDA-5 showed higher dissolution rate compared with other formulations at all time points.
The graphical representation of SDA-1, SDA-2 and SDA-3 with pure ATV was depicted in Figure 1 no endothermic peak for ATV was observed but showed a peak at 59.36˚C
corresponding to PEG-4000. Whereas there is no peak was observed for SDA-5 at 166.41˚C corresponding to the peak of pure drug. But an endothermic peak at 55.92˚C was observed for the mixture of PEG-4000 and Carplex-80, which may be due to interaction between the silica and PEG-4000. These results Figure 3 ).
FTIR Spectral Analysis
FTIR spectrum explored the interaction between pure drug and carrier after SDA preparation (Figure 4 ). An interactive change (N-H stretching) was observed around 2875 cm −1 resulting the reduce intensity of the peak (2875 cm
of PEG-4000 in formulation SDA-2. But a significant N-H stretching was observed at similar wavelength resulting the disappearance of that peak in SDA-5.
SEM Analysis
The SEM photographs of pure ATV, PEG-4000, Carplex-80, mixture of PEG-4000
and Carplex-80 (2:3) and optimized SDA formulations are shown in Figure 5 .
Upon preparation of SD a distinct conversion of crystalline ATV to amorphous state was explored with morphology of SDA formulation. Also, there were a 
In-Vivo Evaluation
Clinical Course
The survival rates in mice among the treatment groups were 100%. None of the mice died in groups SDA, ATV, and vehicle treated DC mice. No sign of physiological and pathological changes were observed during course of treatment.
Changes of Blood Glucose Levels in STZ Induced Diabetic Mice
Time course of changes in blood glucose levels are given in Table 3 . On day 0, before the initiation of treatment the blood glucose levels were significantly higher in STZ induced diabetic mice compared to normal mice (p < 0.001). Oral administration of SDA and ATV significantly lowered the blood glucose levels on days 3, 5 and 7 when compared to DC mice and the effect was dose dependent. Among the treatment groups SDA-H shown most significant attenuation of blood glucose level and the effects of SDA-L on blood glucose level was comparable that of ATV.
Effects of SDA on Body Weight and Organ Weights in Diabetic Mice
Body weight, organ weights and organ weight to body weight ratios are summarized in Table 4 . The body weights and pancreas weight were lower and liver to body weight ratio, the group SDA-H showed significant reduction in liver weight and liver weight to body weight ratio.
Effects of SDA on Lipid Profile and SGPT Levels in Diabetic Mice
The changes in lipid profile and SGPT levels are shown in Table 5 . The data revealed that the levels of TC, TG and LDL were significantly higher and HDL levels were significantly lower in Group DC than that of NC mice.
The increment of TC, TG, LDL and LDL/HDL ratio was significantly attenuated and the level of HDL was increased after oral ingestion of SDA. The
Group SDA-H exhibited greater improvement in lipid profile among the treatment groups. The effects of pure ATV on TC, TG, and HDL were comparable to that of SDA-L.
The DC mice showed higher levels of SGPT indicating inflammation and/or damage in liver. However, administrations of both low and high doses of SDA significantly reduced SGPT levels and were comparable to NC mice. Although treatment with ATV reduced SGPT levels, the effects were not significant.
Histopathology
Representative photomicrographs of thin sections of liver and pancreas stained with hematoxylin-eosin are presented in Figure 6 and The islets from mice of groups DC showed cellular damaging due to the extensive inflammations with complete loss of architecture of pancreatic β-cell.
There was a reduction in the size and number of the islets in untreated DC mice. The diabetic mice treated with SDA restored normal cellular population size of islets, absence of islets damage and presence of hyperplasia. The group ATV mice also showed mild to moderate reduction of necrosis of the islets of pancreas.
Discussion
Drug release is a crucial and limiting step in oral drug bioavailability especially for drugs with low gastrointestinal solubility and high membrane permeability.
The rate of dissolution of active ingredients exhibiting poor aqueous solubility is [29] . Recently, PEG-4000 has been reported to be a step ahead for enhancing drug dissolution and oral bioavailability of ATV [16] .
Carplex is a popular adsorbent and has been known to improve wettebility and dissolution rate of BCS class-II drug [30] . The rationale of the present study was to investigate the use of mixture of PEG-4000 and Carplex-80 (2:3) as a carrier for the preparation of SDA by solvent evaporation method with the objectives of improving dissolution rate of ATV and in-vivo evaluation of SDA in STZ induced diabetic mice.
In our study, SD of ATV was prepared by the solvent evaporation method using PEG-4000 and mixture of PEG-4000 and Carplex-80 as carrier ( Table 1 ).
The physicochemical properties of SD were investigated using differential scanning calorimetry (DSC), X-ray powder diffraction (PXRD), Fourier transforms infrared spectroscopy (FTIR) and scanning electron microscopy (SEM). Our results indicated that the percentage release of ATV from SDA-5 reached around 2 fold higher than that of pure ATV in water medium. This result implied that the hydrophilic properties of PEG-4000 and adsorbent properties Carplex-80 may contributed to the improved wettability and enhanced dissolution of drugs from the SDA. Accordingly, both the amorphous state of the drug and the good wettability of SDA might account for the faster dissolution rate of SDA compared with pure ATV. Whereas, other SDA formulations cannot release the drug significantly after 120 minutes as compared to SDA-5.
Furthermore, the in-vitro dissolution result of our study (Table 2 and Figure   1 ) hence justified the use of effective surface area of carriers for enhancing the dissolution and subsequently its oral bioavailability of ATV in SDA. The improvement of dissolution rate of ATV in SDA was confirmed using different methods and various mechanisms. Commonly, reducing the particle size of the drug is an established mechanism to increase the bioavailability. The mechanism through which crystalline state of ATV is converted to amorphous state was proved using DSC and PXRD analyses. Previously, it was suggested that the drug molecules were adsorbed onto the surface of the porous materials due to the mixing or heating method converting to amorphous state [31] [32] . In DSC thermograms of SDA-5, the complete disappearance of the sharp endothermic ) could improve the wettability properties of the drug and further increase drug dissolution rates [33] . FTIR spectrum of SDA-5 explored that a significant interactive change (N-H stretching) was observed around the wavelength of 2875 cm In the present study, STZ-induced diabetic mice resulted in significant hyperglycemia, hypoinsulinemia and weight loss, indicating that diabetic was implicated in metabolic disorder and serious malabsorption syndrome. Furthermore, chronic high blood glucose can lead to a series of adverse comorbidities, such as kidney impairment, neurological lesion, and cardiovascular risks [34] . In hyperglycemia-mediated diabetes, therapeutic strategy aims to maintain blood glucose that ATV therapy lower blood sugar in diabetic mice accompanied by the benefits of insulin enhancement and body weight increment [9] . STZ-induced diabetic causes decreased in body weight, pancreas weight but increased in liver weight. After 7 days of treatment with SDA increased body weights, pancreas weights and pancreas weight to body weight ratios, but the effects were not significant. Furthermore, treatment with SDA significantly decreased liver weight and liver weight to body weight ratio than that of ATV group.
Dyslipidemia is regarded as a potential risk factor for diabetes or cardiovascular disease [35] . High-density lipoprotein (HDL) containing lipid and protein components show biologically active roles, such as inhibition of oxidative stress and inflammation and may protects against diabetes [36] . Low-density lipoprotein (LDL) deposition increases the risk for cardiovascular disorder related to damaged endothelium and existed oxidized stress. Similarly, increasing LDL concentrations may result in emergence of diabetes [37] . Therefore, effectively Ahmed et al. reported that ATV showed a highly significant fall in the levels of serum cholesterol, triglycerides, and LDL-cholesterol in STZ induced diabetic rats [38] . Together, these SDA mediated benefits might have improved metabolism of glucose and insulin in diabetic mice.
In histopathology study, liver from DC mice showed cellular inflammations and accumulation of lipids which was evidenced by increased in liver weight and expression of higher SGPT levels. Hepatotoxicity is associated with the activation of many membrane damaging enzymes like ATPase, phospholipases, proteases and endonucleases, disruption of mitochondrial metabolism and ATP synthesis; and damage of microfilaments used to support cell structure [39] .
Administration of SDA significantly reduced SGPT levels, the effects of ATV on SGPT levels was not significant. Although, ATV alone could not preserved liver 
Conclusion
Preparation of SD of ATV using mixture of PEG-4000 and Carplex-80 ( 
